{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:26:39Z","timestamp":1790483199621,"version":"4.1.0"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41584-024-01181-x","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T13:02:32Z","timestamp":1730898152000},"page":"795-808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The management of adult and paediatric uveitis for rheumatologists"],"prefix":"10.1038","volume":"20","author":[{"given":"Sarah L. N.","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-3901","authenticated-orcid":false,"given":"Panagiotis","family":"Maghsoudlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Guly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0742-3159","authenticated-orcid":false,"given":"Andrew D.","family":"Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-2401","authenticated-orcid":false,"given":"Athimalaipet V.","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"1181_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ajo.2013.03.027","volume":"156","author":"DA Jabs","year":"2013","unstructured":"Jabs, D. A. & Busingye, J. Approach to the diagnosis of the uveitides. Am. J. Ophthalmol. 156, 228\u2013236 (2013).","journal-title":"Am. J. Ophthalmol."},{"key":"1181_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/09286580802478724","volume":"15","author":"DA Jabs","year":"2008","unstructured":"Jabs, D. A. Epidemiology of uveitis. Ophthalmic Epidemiol. 15, 283\u2013284 (2008).","journal-title":"Ophthalmic Epidemiol."},{"key":"1181_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.5301\/ejo.5000278","volume":"23","author":"E Miserocchi","year":"2013","unstructured":"Miserocchi, E., Fogliato, G., Modorati, G. & Bandello, F. Review on the worldwide epidemiology of uveitis. Eur. J. Ophthalmol. 23, 705\u2013717 (2013).","journal-title":"Eur. J. Ophthalmol."},{"key":"1181_CR4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs, D. A., Nussenblatt, R. B., Rosenbaum, J. T. & Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am. J. Ophthalmol. 140, 509\u2013516 (2005).","journal-title":"Am. J. Ophthalmol."},{"key":"1181_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3414\/ME12-01-0063","volume":"52","author":"B Trusko","year":"2013","unstructured":"Trusko, B. et al. The Standardization of Uveitis Nomenclature (SUN) Project. Development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf. Med. 52, 259\u2013265 (2013). s251\u2013256.","journal-title":"Methods Inf. Med."},{"key":"1181_CR6","doi-asserted-by":"crossref","unstructured":"Chang, M. H., Shantha, J. G., Fondriest, J. J., Lo, M. S. & Angeles-Han, S. T. in: Rheumatic Disease Clinics of North America. 47, 619-641 (W.B. Saunders, 2021).","DOI":"10.1016\/j.rdc.2021.07.005"},{"key":"1181_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaapos.2008.03.007","volume":"12","author":"K Sabri","year":"2008","unstructured":"Sabri, K., Saurenmann, R. K., Silverman, E. D. & Levin, A. V. Course, complications, and outcome of juvenile arthritis-related uveitis. J. AAPOS 12, 539\u2013545 (2008).","journal-title":"J. AAPOS"},{"key":"1181_CR8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ophtha.2020.08.024","volume":"128","author":"V Rypdal","year":"2021","unstructured":"Rypdal, V. et al. Uveitis in juvenile idiopathic arthritis: 18-year outcome in the population-based Nordic cohort study. Ophthalmology 128, 598\u2013608 (2021).","journal-title":"Ophthalmology"},{"key":"1181_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/09273948.2016.1175642","volume":"24","author":"LJ Kopplin","year":"2016","unstructured":"Kopplin, L. J., Mount, G. & Suhler, E. B. Review for disease of the year: epidemiology of HLA-B27 associated ocular disorders. Ocul. Immunol. Inflamm. 24, 470\u2013475 (2016).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1181_CR10","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000909","volume":"8","author":"A Abraham","year":"2020","unstructured":"Abraham, A., Nicholson, L., Dick, A., Rice, C. & Atan, D. Intermediate uveitis associated with MS: diagnosis, clinical features, pathogenic mechanisms, and recommendations for management. Neurol. Neuroimmunol. Neuroinflamm. 8, e909 (2020).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1181_CR11","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1080\/09273948.2023.2293922","volume":"32","author":"EO Kreps","year":"2024","unstructured":"Kreps, E. O. et al. Long-term visual outcome of patients with Blau syndrome. Ocul. Immunol. Inflamm. 32, 1728\u20131732 (2024).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1181_CR12","doi-asserted-by":"publisher","first-page":"102351","DOI":"10.1016\/j.autrev.2019.102351","volume":"18","author":"PJ Bertrand","year":"2019","unstructured":"Bertrand, P. J. et al. Uveitis: autoimmunity\u2026 and beyond. Autoimmun. Rev. 18, 102351 (2019).","journal-title":"Autoimmun. Rev."},{"key":"1181_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/art.503","volume":"46","author":"JR Smith","year":"2002","unstructured":"Smith, J. R. & Rosenbaum, J. T. Management of uveitis: a rheumatologic perspective. Arthritis Rheum. 46, 309\u2013318 (2002).","journal-title":"Arthritis Rheum."},{"key":"1181_CR14","doi-asserted-by":"publisher","first-page":"695904","DOI":"10.3389\/fmed.2021.695904","volume":"8","author":"KA Joltikov","year":"2021","unstructured":"Joltikov, K. A. & Lobo-Chan, A. M. Epidemiology and risk factors in non-infectious uveitis: a systematic review. Front. Med. 8, 695904 (2021).","journal-title":"Front. Med."},{"key":"1181_CR15","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1080\/09273948.2023.2282610","volume":"31","author":"P Maghsoudlou","year":"2023","unstructured":"Maghsoudlou, P. et al. Uveitis associated with monogenic autoinflammatory syndromes in children. Ocul. Immunol. Inflamm. 31, 1930\u20131943 (2023).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1181_CR16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals, M. et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 86, 242\u2013251 (2007).","journal-title":"Medicine"},{"key":"1181_CR17","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1002\/art.22918","volume":"56","author":"LL Lim","year":"2007","unstructured":"Lim, L. L., Fraunfelder, F. W. & Rosenbaum, J. T. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 56, 3248\u20133252 (2007).","journal-title":"Arthritis Rheum."},{"key":"1181_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/jop.2022.0094","volume":"39","author":"NA Chartrand","year":"2023","unstructured":"Chartrand, N. A. et al. Ocular side effects of bisphosphonates: a review of literature. J. Ocul. Pharmacol. Ther. 39, 3\u201316 (2023).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"1181_CR19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/ard.2007.077370","volume":"67","author":"LC Coates","year":"2008","unstructured":"Coates, L. C., McGonagle, D. G., Bennett, A. N., Emery, P. & Marzo-Ortega, H. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. Ann. Rheum. Dis. 67, 729\u2013730 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"1181_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-020-00202-6","volume":"10","author":"F Nicolela Susanna","year":"2020","unstructured":"Nicolela Susanna, F. & Pavesio, C. A review of ocular adverse events of biological anti-TNF drugs. J. Ophthalmic Inflamm. Infect. 10, 11 (2020).","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"1181_CR21","doi-asserted-by":"publisher","first-page":"115887","DOI":"10.1016\/j.bone.2021.115887","volume":"146","author":"P Peris","year":"2021","unstructured":"Peris, P., Monegal, A. & Guanabens, N. Bisphosphonates in inflammatory rheumatic diseases. Bone 146, 115887 (2021).","journal-title":"Bone"},{"key":"1181_CR22","doi-asserted-by":"publisher","first-page":"102454","DOI":"10.1016\/j.jaut.2020.102454","volume":"111","author":"C Anquetil","year":"2020","unstructured":"Anquetil, C. et al. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO\u2019s pharmacovigilance database. J. Autoimmun. 111, 102454 (2020).","journal-title":"J. Autoimmun."},{"key":"1181_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1136\/ard.62.4.378","volume":"62","author":"P Fietta","year":"2003","unstructured":"Fietta, P., Manganelli, P. & Lodigiani, L. Clodronate induced uveitis. Ann. Rheum. Dis. 62, 378 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"1181_CR24","doi-asserted-by":"publisher","first-page":"623725","DOI":"10.3389\/fimmu.2021.623725","volume":"12","author":"CE Egwuagu","year":"2021","unstructured":"Egwuagu, C. E., Alhakeem, S. A. & Mbanefo, E. C. Uveitis: molecular pathogenesis and emerging therapies. Front. Immunol. 12, 623725 (2021).","journal-title":"Front. Immunol."},{"key":"1181_CR25","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11926-006-0006-6","volume":"8","author":"RW Read","year":"2006","unstructured":"Read, R. W. Uveitis: advances in understanding of pathogenesis and treatment. Curr. Rheumatol. Rep. 8, 260\u2013266 (2006).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1181_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease.","year":"2014","unstructured":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease. The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J. Eur. Acad. Dermatol. Venereol. 28, 338\u2013347 (2014).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1181_CR27","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/ard.2009.108217","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M. et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann. Rheum. Dis. 68, 770\u2013776 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1181_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit, M. et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann. Rheum. Dis. 70, 25\u201331 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1181_CR29","first-page":"19","volume":"31","author":"MA Judson","year":"2014","unstructured":"Judson, M. A. et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc. Diffus. Lung Dis. 31, 19\u201327 (2014).","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"1181_CR30","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty, R. E. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31, 390\u2013392 (2004).","journal-title":"J. Rheumatol."},{"key":"1181_CR31","first-page":"524","volume":"31","author":"J Fern\u00e1ndez-Mel\u00f3n","year":"2004","unstructured":"Fern\u00e1ndez-Mel\u00f3n, J. et al. Uveitis as the initial clinical manifestation in patients with spondyloarthropathies. J. Rheumatol. 31, 524\u2013527 (2004).","journal-title":"J. Rheumatol."},{"key":"1181_CR32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2021.03.058","volume":"228","author":"Standardization of Uveitis Nomenclature Working Group.","year":"2021","unstructured":"Standardization of Uveitis Nomenclature Working Group. Classification criteria for Beh\u00e7et disease uveitis. Am. J. Ophthalmol. 228, 80\u201388 (2021).","journal-title":"Am. J. Ophthalmol."},{"key":"1181_CR33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ajo.2021.03.055","volume":"228","author":"Standardization of Uveitis Nomenclature Working Group.","year":"2021","unstructured":"Standardization of Uveitis Nomenclature Working Group. Classification criteria for juvenile idiopathic arthritis-associated chronic anterior uveitis. Am. J. Ophthalmol. 228, 192\u2013197 (2021).","journal-title":"Am. J. Ophthalmol."},{"key":"1181_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ajo.2021.03.049","volume":"228","author":"Standardization of Uveitis Nomenclature Working Group.","year":"2021","unstructured":"Standardization of Uveitis Nomenclature Working Group. Classification criteria for spondyloarthritis\/HLA-B27-associated anterior uveitis. Am. J. Ophthalmol. 228, 117\u2013125 (2021).","journal-title":"Am. J. Ophthalmol."},{"key":"1181_CR35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ajo.2021.03.047","volume":"228","author":"Standardization of Uveitis Nomenclature Working Group","year":"2021","unstructured":"Standardization of Uveitis Nomenclature Working Group Classification criteria for sarcoidosis-associated uveitis. Am. J. Ophthalmol. 228, 220\u2013230 (2021).","journal-title":"Am. J. Ophthalmol."},{"key":"1181_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ajo.2022.04.007","volume":"241","author":"LI Mudie","year":"2022","unstructured":"Mudie, L. I. et al. Evaluation of the SUN classification criteria for uveitides in an academic uveitis practice. Am. J. Ophthalmol. 241, 57\u201363 (2022).","journal-title":"Am. J. Ophthalmol."},{"key":"1181_CR37","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1136\/annrheumdis-2016-209686","volume":"76","author":"JB Kuemmerle-Deschner","year":"2017","unstructured":"Kuemmerle-Deschner, J. B. et al. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Ann. Rheum. Dis. 76, 942\u2013947 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1181_CR38","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","volume":"125","author":"AD Dick","year":"2018","unstructured":"Dick, A. D. et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology 125, 757\u2013773 (2018).","journal-title":"Ophthalmology"},{"key":"1181_CR39","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/art.40885","volume":"71","author":"ST Angeles-Han","year":"2019","unstructured":"Angeles-Han, S. T. et al. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Rheumatol. 71, 864\u2013877 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"1181_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/09273948.2016.1196713","volume":"26","author":"T Tsirouki","year":"2018","unstructured":"Tsirouki, T. et al. A focus on the epidemiology of uveitis. Ocul. Immunol. Inflamm. 26, 2\u201316 (2018).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1181_CR41","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.ophtha.2015.06.041","volume":"122","author":"S Kothari","year":"2015","unstructured":"Kothari, S. et al. The risk of intraocular pressure elevation in pediatric noninfectious uveitis. Ophthalmology 122, 1987\u20132001 (2015).","journal-title":"Ophthalmology"},{"key":"1181_CR42","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.ophtha.2009.12.003","volume":"117","author":"JE Thorne","year":"2010","unstructured":"Thorne, J. E., Woreta, F. A., Dunn, J. P. & Jabs, D. A. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 117, 1436\u20131441 (2010).","journal-title":"Ophthalmology"},{"key":"1181_CR43","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/j.ophtha.2014.05.021","volume":"121","author":"HN Sen","year":"2014","unstructured":"Sen, H. N. et al. Periocular corticosteroid injections in uveitis: effects and complications. Ophthalmology 121, 2275\u20132286 (2014).","journal-title":"Ophthalmology"},{"key":"1181_CR44","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1167\/iovs.12-10981","volume":"54","author":"S Lightman","year":"2013","unstructured":"Lightman, S. et al. Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis. Investig. Ophthalmol. Vis. Sci. 54, 4864\u20134870 (2013).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"1181_CR45","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","volume":"129","author":"C Lowder","year":"2011","unstructured":"Lowder, C. et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch. Ophthalmol. 129, 545\u2013553 (2011).","journal-title":"Arch. Ophthalmol."},{"key":"1181_CR46","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.ophtha.2005.03.013","volume":"112","author":"GJ Jaffe","year":"2005","unstructured":"Jaffe, G. J. et al. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 112, 1192\u20131198(2005).","journal-title":"Ophthalmology"},{"key":"1181_CR47","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","volume":"126","author":"JE Thorne","year":"2019","unstructured":"Thorne, J. E. et al. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology 126, 283\u2013295 (2019).","journal-title":"Ophthalmology"},{"key":"1181_CR48","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1001\/archopht.126.9.1191","volume":"126","author":"DG Callanan","year":"2008","unstructured":"Callanan, D. G., Jaffe, G. J., Martin, D. F., Pearson, P. A. & Comstock, T. L. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch. Ophthalmol. 126, 1191\u20131201 (2008).","journal-title":"Arch. Ophthalmol."},{"key":"1181_CR49","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.ophtha.2015.06.042","volume":"122","author":"Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group.","year":"2015","unstructured":"Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty-four-month results of the Multicenter Uveitis Steroid Treatment (MUST) trial and follow-up study. Ophthalmology 122, 1967\u20131975 (2015).","journal-title":"Ophthalmology"},{"key":"1181_CR50","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","volume":"127","author":"S Yeh","year":"2020","unstructured":"Yeh, S. et al. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial. Ophthalmology 127, 948\u2013955 (2020).","journal-title":"Ophthalmology"},{"key":"1181_CR51","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1111\/j.1755-3768.2010.02025.x","volume":"88","author":"Z Habot-Wilner","year":"2010","unstructured":"Habot-Wilner, Z. et al. Periocular corticosteroid injection in the management of uveitis in children. Acta Ophthalmol. 88, e299\u2013e304 (2010).","journal-title":"Acta Ophthalmol."},{"key":"1181_CR52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2017.08.007","volume":"125","author":"DA Jabs","year":"2018","unstructured":"Jabs, D. A. Immunosuppression for the uveitides. Ophthalmology 125, 193\u2013202 (2018).","journal-title":"Ophthalmology"},{"key":"1181_CR53","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/ard.2005.038638","volume":"65","author":"JA Da Silva","year":"2006","unstructured":"Da Silva, J. A. et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann. Rheum. Dis. 65, 285\u2013293 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"1181_CR54","first-page":"1107","volume":"77","author":"T Constantin","year":"2018","unstructured":"Constantin, T. et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann. Rheum. Dis. 77, 1107\u20131117 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1181_CR55","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ophtha.2010.03.029","volume":"118","author":"QD Nguyen","year":"2011","unstructured":"Nguyen, Q. D. et al. A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. Ophthalmology 118, 184\u2013190 (2011).","journal-title":"Ophthalmology"},{"key":"1181_CR56","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3390\/jcm13051402","volume":"13","author":"M Esteban-Ortega","year":"2024","unstructured":"Esteban-Ortega, M. et al. An observational study in the real clinical practice of the treatment of noninfectious uveitis. J. Clin. Med. 13, 1402 (2024).","journal-title":"J. Clin. Med."},{"key":"1181_CR57","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","volume":"130","author":"DA Jabs","year":"2000","unstructured":"Jabs, D. A. et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am. J. Ophthalmol. 130, 492\u2013513 (2000).","journal-title":"Am. J. Ophthalmol."},{"key":"1181_CR58","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/bjophthalmol-2017-310156","volume":"102","author":"CME Deuter","year":"2018","unstructured":"Deuter, C. M. E. et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. Br. J. Ophthalmol. 102, 647\u2013653 (2018).","journal-title":"Br. J. Ophthalmol."},{"key":"1181_CR59","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"H Yazici","year":"1990","unstructured":"Yazici, H. et al. A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome. N. Engl. J. Med. 322, 281\u2013285 (1990).","journal-title":"N. Engl. J. Med."},{"key":"1181_CR60","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jama.2019.12618","volume":"322","author":"SR Rathinam","year":"2019","unstructured":"Rathinam, S. R. et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA 322, 936\u2013945, (2019).","journal-title":"JAMA"},{"key":"1181_CR61","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1001\/archopht.123.5.634","volume":"123","author":"CC Murphy","year":"2005","unstructured":"Murphy, C. C. et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch. Ophthalmol. 123, 634\u2013641 (2005).","journal-title":"Arch. Ophthalmol."},{"key":"1181_CR62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/09286580701585892","volume":"15","author":"JH Kempen","year":"2008","unstructured":"Kempen, J. H. et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) cohort study. Ophthalmic Epidemiol. 15, 47\u201355 (2008).","journal-title":"Ophthalmic Epidemiol."},{"key":"1181_CR63","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","volume":"116","author":"S Gangaputra","year":"2009","unstructured":"Gangaputra, S. et al. Methotrexate for ocular inflammatory diseases. Ophthalmology 116, 2188\u20132198.e2181 (2009).","journal-title":"Ophthalmology"},{"key":"1181_CR64","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","volume":"149","author":"E Daniel","year":"2010","unstructured":"Daniel, E. et al. Mycophenolate mofetil for ocular inflammation. Am. J. Ophthalmol. 149, 423\u2013432.e421-422 (2010).","journal-title":"Am. J. Ophthalmol."},{"key":"1181_CR65","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","volume":"148","author":"S Pasadhika","year":"2009","unstructured":"Pasadhika, S. et al. Azathioprine for ocular inflammatory diseases. Am. J. Ophthalmol. 148, 500\u2013509.e2 (2009).","journal-title":"Am. J. Ophthalmol."},{"key":"1181_CR66","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","volume":"117","author":"RO Ka\u00e7maz","year":"2010","unstructured":"Ka\u00e7maz, R. O. et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 117, 576\u2013584 (2010).","journal-title":"Ophthalmology"},{"key":"1181_CR67","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/eye.2000.84","volume":"14","author":"JM Benitez-Del-Castillo","year":"2000","unstructured":"Benitez-Del-Castillo, J. M., Garcia-Sanchez, J., Iradier, T. & Ba\u00f1ares, A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 14, 340\u2013343 (2000).","journal-title":"Eye"},{"key":"1181_CR68","first-page":"1277","volume":"30","author":"S Mu\u00f1oz-Fern\u00e1ndez","year":"2003","unstructured":"Mu\u00f1oz-Fern\u00e1ndez, S. et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J. Rheumatol. 30, 1277\u20131279 (2003).","journal-title":"J. Rheumatol."},{"key":"1181_CR69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro, S. et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann. Rheum. Dis. 82, 19\u201334 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1181_CR70","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/17469899.2017.1319762","volume":"12","author":"JE Knickelbein","year":"2017","unstructured":"Knickelbein, J. E., Kim, M., Argon, E., Nussenblatt, R. B. & Sen, N. H. Comparative efficacy of steroid-sparing therapies for non-infectious uveitis. Expert Rev. Ophthalmol. 12, 313\u2013319 (2017).","journal-title":"Expert Rev. Ophthalmol."},{"key":"1181_CR71","first-page":"362","volume":"32","author":"I Foeldvari","year":"2005","unstructured":"Foeldvari, I. & Wierk, A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J. Rheumatol. 32, 362\u2013365 (2005).","journal-title":"J. Rheumatol."},{"key":"1181_CR72","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/112067210701700509","volume":"17","author":"A Heiligenhaus","year":"2007","unstructured":"Heiligenhaus, A., Mingels, A., Heinz, C. & Ganser, G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur. J. Ophthalmol. 17, 743\u2013748 (2007).","journal-title":"Eur. J. Ophthalmol."},{"key":"1181_CR73","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jpeds.2013.03.047","volume":"163","author":"C Papadopoulou","year":"2013","unstructured":"Papadopoulou, C. et al. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J. Pediatr. 163, 879\u2013884 (2013).","journal-title":"J. Pediatr."},{"key":"1181_CR74","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3928\/0191-3913-19990501-09","volume":"36","author":"AK Shetty","year":"1999","unstructured":"Shetty, A. K., Zganjar, B. E., Ellis, G. S. Jr., Ludwig, I. H. & Gedalia, A. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. J. Pediatr. Ophthalmol. Strabismus 36, 125\u2013128 (1999).","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"1181_CR75","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/09273948.2017.1411518","volume":"26","author":"F Mackensen","year":"2018","unstructured":"Mackensen, F. et al. Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis. Ocul. Immunol. Inflamm. 26, 1015\u20131022 (2018).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1181_CR76","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe, G. J. et al. Adalimumab in patients with active noninfectious uveitis. N. Engl. J. Med. 375, 932\u2013943 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1181_CR77","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen, Q. D. et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388, 1183\u20131192 (2016).","journal-title":"Lancet"},{"key":"1181_CR78","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","volume":"125","author":"EB Suhler","year":"2018","unstructured":"Suhler, E. B. et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology 125, 1075\u20131087 (2018).","journal-title":"Ophthalmology"},{"key":"1181_CR79","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/ard.2008.092585","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M. et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann. Rheum. Dis. 68, 696\u2013701 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1181_CR80","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/bcp.15101","volume":"88","author":"N Garc\u00eda-Beloso","year":"2022","unstructured":"Garc\u00eda-Beloso, N. et al. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: a systematic literature review. Br. J. Clin. Pharmacol. 88, 1529\u20131550 (2022).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1181_CR81","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1080\/09273948.2023.2295544","volume":"32","author":"SH Song","year":"2024","unstructured":"Song, S. H. & Woo, S. J. Efficacy and safety of switching from adalimumab originator to SB5, adalimumab biosimilar for noninfectious uveitis. Ocul. Immunol. Inflamm. 32, 1755\u20131759 (2024).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1181_CR82","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/archopht.123.7.903","volume":"123","author":"EB Suhler","year":"2005","unstructured":"Suhler, E. B. et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch. Ophthalmol. 123, 903\u2013912, (2005).","journal-title":"Arch. Ophthalmol."},{"key":"1181_CR83","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ophtha.2013.07.019","volume":"121","author":"JN Kruh","year":"2014","unstructured":"Kruh, J. N., Yang, P., Suelves, A. M. & Foster, C. S. Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up. Ophthalmology 121, 358\u2013364 (2014).","journal-title":"Ophthalmology"},{"key":"1181_CR84","doi-asserted-by":"publisher","first-page":"1095423","DOI":"10.3389\/fmed.2023.1095423","volume":"10","author":"M Takeuchi","year":"2023","unstructured":"Takeuchi, M. et al. Ten-year follow-up of infliximab treatment for uveitis in Beh\u00e7et disease patients: a multicenter retrospective study. Front. Med. 10, 1095423 (2023).","journal-title":"Front. Med."},{"key":"1181_CR85","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00296-009-1213-z","volume":"31","author":"A Giardina","year":"2011","unstructured":"Giardina, A. et al. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh\u00e7et\u2019s disease refractory to standard immunosuppressive drugs. Rheumatol. Int. 31, 33\u201337 (2011).","journal-title":"Rheumatol. Int."},{"key":"1181_CR86","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.semarthrit.2016.03.002","volume":"46","author":"V Calvo-R\u00edo","year":"2016","unstructured":"Calvo-R\u00edo, V. et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin. Arthritis Rheum. 46, 95\u2013101 (2016).","journal-title":"Semin. Arthritis Rheum."},{"key":"1181_CR87","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/09273948.2022.2081584","volume":"31","author":"K Okada","year":"2023","unstructured":"Okada, K., Zhou, Y., Hashida, N., Takagi, T. & Tian, Y. S. The efficacy of golimumab against non-infectious uveitis: a PRISMA-compliant systematic review and meta-analysis. Ocul. Immunol. Inflamm. 31, 1013\u20131023 (2023).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1181_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52526-1","volume":"14","author":"U Tungsattayathitthan","year":"2024","unstructured":"Tungsattayathitthan, U. et al. Efficacy of golimumab in patients with refractory non-infectious panuveitis. Sci. Rep. 14, 2179 (2024).","journal-title":"Sci. Rep."},{"key":"1181_CR89","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/acr.22848","volume":"68","author":"M Rudwaleit","year":"2016","unstructured":"Rudwaleit, M. et al. Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. Arthritis Care Res. 68, 838\u2013844 (2016).","journal-title":"Arthritis Care Res."},{"key":"1181_CR90","doi-asserted-by":"publisher","first-page":"1759720x2110038","DOI":"10.1177\/1759720X211003803","volume":"13","author":"IE van der Horst-Bruinsma","year":"2021","unstructured":"van der Horst-Bruinsma, I. E. et al. Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study. Ther. Adv. Musculoskelet. Dis. 13, 1759720x211003803 (2021).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"1181_CR91","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/archopht.121.4.437","volume":"121","author":"CS Foster","year":"2003","unstructured":"Foster, C. S. et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch. Ophthalmol. 121, 437\u2013440 (2003).","journal-title":"Arch. Ophthalmol."},{"key":"1181_CR92","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1185\/03007995.2014.993024","volume":"31","author":"P Brito-Zer\u00f3n","year":"2015","unstructured":"Brito-Zer\u00f3n, P., Perez-Alvarez, R. & Ramos-Casals, M. Etanercept and uveitis: friends or foes? Curr. Med. Res. Opin. 31, 251\u2013252 (2015).","journal-title":"Curr. Med. Res. Opin."},{"key":"1181_CR93","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke, G. et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121, 785\u2013796.e3 (2014).","journal-title":"Ophthalmology"},{"key":"1181_CR94","first-page":"3194 \u2013 A0420","volume":"63","author":"M McHarg","year":"2022","unstructured":"McHarg, M. et al. Anti-drug antibodies to monoclonal TNF inhibitors in non-infectious uveitis. Investig. Ophthalmol. Vis. Sci. 63, 3194 \u2013 A0420\u20133194 \u2013 A0420 (2022).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"1181_CR95","first-page":"1043","volume":"35","author":"ST Leinonen","year":"2017","unstructured":"Leinonen, S. T., Aalto, K., Kotaniemi, K. M. & Kivel\u00e4, T. T. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis. Clin. Exp. Rheumatol. 35, 1043\u20131046 (2017).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1181_CR96","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert, F. et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N. Engl. J. Med. 348, 601\u2013608 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1181_CR97","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3899\/jrheum.160072","volume":"44","author":"FA Aeschlimann","year":"2017","unstructured":"Aeschlimann, F. A. et al. Prevalence of anti-infliximab antibodies and their associated co-factors in children with refractory arthritis and\/or uveitis: a retrospective longitudinal cohort study. J. Rheumatol. 44, 334\u2013341 (2017).","journal-title":"J. Rheumatol."},{"key":"1181_CR98","doi-asserted-by":"publisher","first-page":"101634","DOI":"10.1016\/j.ajoc.2022.101634","volume":"27","author":"L Valdes","year":"2022","unstructured":"Valdes, L. et al. Anti-infliximab antibodies and clinical response in noninfectious uveitis and scleritis patients treated with infliximab: a retrospective review. Am. J. Ophthalmol. Case Rep. 27, 101634 (2022).","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"1181_CR99","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41433-023-02795-3","volume":"38","author":"EO Kreps","year":"2024","unstructured":"Kreps, E. O. et al. Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy. Eye 38, 871\u2013876 (2024).","journal-title":"Eye"},{"key":"1181_CR100","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","volume":"120","author":"AD Dick","year":"2013","unstructured":"Dick, A. D. et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120, 777\u2013787 (2013).","journal-title":"Ophthalmology"},{"key":"1181_CR101","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","volume":"122","author":"E Letko","year":"2015","unstructured":"Letko, E. et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology 122, 939\u2013948 (2015).","journal-title":"Ophthalmology"},{"key":"1181_CR102","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.reuma.2023.07.002","volume":"19","author":"E Beltr\u00e1n Catal\u00e1n","year":"2023","unstructured":"Beltr\u00e1n Catal\u00e1n, E. et al. SER recommendations for the treatment of uveitis. Reumatol. Cl\u00edn. 19, 465\u2013477 (2023).","journal-title":"Reumatol. Cl\u00edn."},{"key":"1181_CR103","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225933","author":"MA Brown","year":"2024","unstructured":"Brown, M. A. et al. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b\/3 trials. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/ard-2024-225933 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1181_CR104","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1136\/bjophthalmol-2021-320604","volume":"107","author":"M Hassan","year":"2023","unstructured":"Hassan, M. et al. Utilisation of composite endpoint outcome to assess efficacy of tocilizumab for non-infectious uveitis in the STOP-Uveitis Study. Br. J. Ophthalmol. 107, 1197\u20131201 (2023).","journal-title":"Br. J. Ophthalmol."},{"key":"1181_CR105","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","volume":"183","author":"YJ Sepah","year":"2017","unstructured":"Sepah, Y. J. et al. Primary (month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am. J. Ophthalmol. 183, 71\u201380 (2017).","journal-title":"Am. J. Ophthalmol."},{"key":"1181_CR106","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/S2665-9913(20)30008-4","volume":"2","author":"AV Ramanan","year":"2020","unstructured":"Ramanan, A. V. et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2, e135\u2013e141 (2020).","journal-title":"Lancet Rheumatol."},{"key":"1181_CR107","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ophtha.2018.09.044","volume":"126","author":"J Heissigerov\u00e1","year":"2019","unstructured":"Heissigerov\u00e1, J. et al. Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study. Ophthalmology 126, 428\u2013437 (2019).","journal-title":"Ophthalmology"},{"key":"1181_CR108","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/bjo-2022-321585","volume":"108","author":"PP Schauwvlieghe","year":"2024","unstructured":"Schauwvlieghe, P. P., Van Calster, J., Herbort, C. P. Jr., Kestelyn, P. A. & de Vlam, K. Efficacy and safety of abatacept to treat active birdshot uveitis: a prospective open label interventional proof-of-concept trial. Br. J. Ophthalmol. 108, 244\u2013252 (2024).","journal-title":"Br. J. Ophthalmol."},{"key":"1181_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-021-00252-4","volume":"11","author":"CC Ng","year":"2021","unstructured":"Ng, C. C., Sy, A. & Cunningham, E. T. Jr. Rituximab for non-infectious uveitis and scleritis. J. Ophthalmic Inflamm. Infect. 11, 23 (2021).","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"1181_CR110","doi-asserted-by":"publisher","first-page":"2324400","DOI":"10.1155\/2021\/2324400","volume":"2021","author":"J Wen","year":"2021","unstructured":"Wen, J. et al. Role of Janus kinase (JAK) inhibitor in autoimmune ocular inflammation: a systematic review. J. Immunol. Res. 2021, 2324400 (2021).","journal-title":"J. Immunol. Res."},{"key":"1181_CR111","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamaophthalmol.2024.2439","volume":"142","author":"SK Srivastava","year":"2024","unstructured":"Srivastava, S. K. et al. Filgotinib in active noninfectious uveitis: the HUMBOLDT randomized clinical trial. JAMA Ophthalmol. 142, 789\u2013797 (2024).","journal-title":"JAMA Ophthalmol."},{"key":"1181_CR112","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","volume":"376","author":"AV Ramanan","year":"2017","unstructured":"Ramanan, A. V. et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N. Engl. J. Med. 376, 1637\u20131646 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1181_CR113","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","volume":"77","author":"P Quartier","year":"2018","unstructured":"Quartier, P. et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann. Rheum. Dis. 77, 1003\u20131011 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1181_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04796-z","volume":"21","author":"NR Acharya","year":"2020","unstructured":"Acharya, N. R. et al. Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial. Trials 21, 887 (2020).","journal-title":"Trials"},{"key":"1181_CR115","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ajo.2019.06.007","volume":"207","author":"S Horton","year":"2019","unstructured":"Horton, S. et al. Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the Bristol participants of the SYCAMORE Trial. Am. J. Ophthalmol. 207, 170\u2013174 (2019).","journal-title":"Am. J. Ophthalmol."},{"key":"1181_CR116","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","volume":"113","author":"P Kahn","year":"2006","unstructured":"Kahn, P., Weiss, M., Imundo, L. F. & Levy, D. M. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 113, 860\u2013864.e862 (2006).","journal-title":"Ophthalmology"},{"key":"1181_CR117","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.3899\/jrheum.121180","volume":"40","author":"MA Lerman","year":"2013","unstructured":"Lerman, M. A. et al. Response of pediatric uveitis to tumor necrosis factor-\u03b1 inhibitors. J. Rheumatol. 40, 1394\u20131403 (2013).","journal-title":"J. Rheumatol."},{"key":"1181_CR118","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3899\/jrheum.160231","volume":"43","author":"C Tappeiner","year":"2016","unstructured":"Tappeiner, C. et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J. Rheumatol. 43, 2183\u20132188 (2016).","journal-title":"J. Rheumatol."},{"key":"1181_CR119","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41927-018-0010-2","volume":"2","author":"AV Ramanan","year":"2018","unstructured":"Ramanan, A. V. et al. A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). BMC Rheumatol. 2, 4 (2018).","journal-title":"BMC Rheumatol."},{"key":"1181_CR120","unstructured":"International Clinical Trials Registry Platform. A study to see whether adalimumab or secukinumab is better for treating children and young people with juvenile idiopathic arthritis (JIA) associated uveitis or chronic anterior uveitis. WHO https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN12427150 (2023)."},{"key":"1181_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05651-5","volume":"22","author":"AV Ramanan","year":"2021","unstructured":"Ramanan, A. V. et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials 22, 689 (2021).","journal-title":"Trials"},{"key":"1181_CR122","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1080\/09273948.2021.2017152","volume":"29","author":"EC ET","year":"2021","unstructured":"ET, E. C. & Zierhut, M. Vision loss in uveitis. Ocul. Immunol. Inflamm. 29, 1037\u20131039 (2021).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1181_CR123","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/j.ophtha.2014.07.007","volume":"121","author":"O Tomkins-Netzer","year":"2014","unstructured":"Tomkins-Netzer, O. et al. Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology 121, 2387\u20132392 (2014).","journal-title":"Ophthalmology"},{"key":"1181_CR124","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/biomedicines11020624","volume":"11","author":"M Ostrovsky","year":"2023","unstructured":"Ostrovsky, M. et al. Ocular Beh\u00e7et disease \u2014 clinical manifestations, treatments and outcomes according to age at disease onset. Biomedicines 11, 624 (2023).","journal-title":"Biomedicines"},{"key":"1181_CR125","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1038\/s41433-022-02216-x","volume":"37","author":"HH Al-Ani","year":"2023","unstructured":"Al-Ani, H. H., Sims, J. L. & Niederer, R. L. Long term complications and vision loss in HLA-B27 uveitis. Eye 37, 1673\u20131677 (2023).","journal-title":"Eye"},{"key":"1181_CR126","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/09273948.2022.2032189","volume":"31","author":"RL Niederer","year":"2023","unstructured":"Niederer, R. L., Sharief, L., Tomkins-Netzer, O. & Lightman, S. L. Uveitis in sarcoidosis - clinical features and comparison with other non-infectious uveitis. Ocul. Immunol. Inflamm. 31, 367\u2013373 (2023).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1181_CR127","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.ophtha.2020.10.036","volume":"128","author":"EB Suhler","year":"2021","unstructured":"Suhler, E. B. et al. Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 128, 899\u2013909 (2021).","journal-title":"Ophthalmology"},{"key":"1181_CR128","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.ophtha.2020.04.001","volume":"127","author":"GJ Jaffe","year":"2020","unstructured":"Jaffe, G. J., Pavesio, C. E. & Study, I. Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results. Ophthalmology 127, 1395\u20131404 (2020).","journal-title":"Ophthalmology"},{"key":"1181_CR129","unstructured":"Royal College of Ophthalmologists & British Society for Paediatric and Adolescent Rheumatology (BSPAR). Guidelines for screening for uveitis in juvenile idiopathic arthritis (JIA). https:\/\/www.rcophth.ac.uk\/resources-listing\/guidelines-for-screening-for-uveitis-in-juvenile-idiopathic-arthritis-jia\/ (2006)."},{"key":"1181_CR130","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/aos.15097","volume":"100","author":"RAW Wennink","year":"2022","unstructured":"Wennink, R. A. W. et al. Improved clinical outcomes in patients with juvenile idiopathic arthritis associated uveitis in the last decade. Acta Ophthalmol. 100, 781\u2013787 (2022).","journal-title":"Acta Ophthalmol."},{"key":"1181_CR131","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12969-018-0266-5","volume":"16","author":"M Cann","year":"2018","unstructured":"Cann, M. et al. Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy. Pediatr. Rheumatol. Online J. 16, 51 (2018).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1181_CR132","doi-asserted-by":"publisher","unstructured":"Paroli, M. P. et al. Persistence of juvenile idiopathic arthritis-associated uveitis in adulthood: a retrospective study. J. Clin. Med. 11, https:\/\/doi.org\/10.3390\/jcm11092471 (2022).","DOI":"10.3390\/jcm11092471"},{"key":"1181_CR133","doi-asserted-by":"publisher","unstructured":"Tordoff, M. et al. O01 Genetic risk factors associated with increased risk of uveitis in patients with juvenile idiopathic arthritis. Rheumatology 60, https:\/\/doi.org\/10.1093\/rheumatology\/keab246 (2021).","DOI":"10.1093\/rheumatology\/keab246"},{"key":"1181_CR134","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ophtha.2017.05.013","volume":"124","author":"A Invernizzi","year":"2017","unstructured":"Invernizzi, A. et al. Objective quantification of anterior chamber inflammation: measuring cells and flare by anterior segment optical coherence tomography. Ophthalmology 124, 1670\u20131677 (2017).","journal-title":"Ophthalmology"},{"key":"1181_CR135","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ajo.2022.05.012","volume":"241","author":"E Tsui","year":"2022","unstructured":"Tsui, E. et al. Quantification of anterior chamber cells in children with uveitis using anterior segment optical coherence tomography. Am. J. Ophthalmol. 241, 254\u2013261 (2022).","journal-title":"Am. J. Ophthalmol."},{"key":"1181_CR136","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1167\/tvst.11.4.7","volume":"11","author":"MA Sorkhabi","year":"2022","unstructured":"Sorkhabi, M. A., Potapenko, I. O., Ilginis, T., Alberti, M. & Cabrerizo, J. Assessment of anterior uveitis through anterior-segment optical coherence tomography and artificial intelligence-based image analyses. Transl. Vis. Sci. Technol. 11, 7 (2022).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"1181_CR137","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1167\/iovs.65.1.9","volume":"65","author":"AL Solebo","year":"2024","unstructured":"Solebo, A. L., Bellchambers, A., Kellett, S., Rahi, J. S. & Dick, A. D. Establishing the normative data set necessary for imaging-based childhood uveitis surveillance: a cross-sectional study. Invest. Ophthalmol. Vis. Sci. 65, 9 (2024).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1181_CR138","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.3390\/jcm11237034","volume":"11","author":"L Garcia-Onrubia","year":"2022","unstructured":"Garcia-Onrubia, L. et al. Tear and plasma levels of cytokines in patients with uveitis: search for active disease biomarkers. J. Clin. Med. 11, 7034 (2022).","journal-title":"J. Clin. Med."},{"key":"1181_CR139","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1080\/09273948.2020.1758731","volume":"29","author":"ST Angeles-Han","year":"2021","unstructured":"Angeles-Han, S. T. et al. S100 proteins, cytokines, and chemokines as tear biomarkers in children with juvenile idiopathic arthritis-associated uveitis. Ocul. Immunol. Inflamm. 29, 1616\u20131620 (2021).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1181_CR140","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00296-016-3593-1","volume":"37","author":"E Pato","year":"2017","unstructured":"Pato, E. et al. Development of an activity disease score in patients with uveitis (UVEDAI). Rheumatol. Int. 37, 647\u2013656 (2017).","journal-title":"Rheumatol. Int."},{"key":"1181_CR141","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s40123-023-00654-8","volume":"12","author":"E Pato-Cour","year":"2023","unstructured":"Pato-Cour, E. et al. Validation of UVEDAI: an index for evaluating the level of inflammatory activity in uveitis. Ophthalmol. Ther. 12, 1045\u20131055 (2023).","journal-title":"Ophthalmol. Ther."},{"key":"1181_CR142","doi-asserted-by":"publisher","unstructured":"Yuan, P. D. et al. Adalimumab dose reduction and withdrawal in stable non-infectious pediatric uveitis: an open-label, prospective, pilot study. Ocul. Immunol. Inflamm. https:\/\/doi.org\/10.1080\/09273948.2024.2343084 (2024).","DOI":"10.1080\/09273948.2024.2343084"},{"key":"1181_CR143","unstructured":"Iapoce, C. NEPTUNE: brepocitinib displays strong efficacy in non-infectious uveitis. HCPLive https:\/\/www.hcplive.com\/view\/neptune-brepocitinib-displays-strong-efficacy-non-infectious-uveitis (2 April 2024)."},{"key":"1181_CR144","doi-asserted-by":"publisher","first-page":"2209920","DOI":"10.1080\/19420862.2023.2209920","volume":"15","author":"S Klint","year":"2023","unstructured":"Klint, S. et al. Izokibep: preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis. MAbs 15, 2209920 (2023).","journal-title":"MAbs"},{"key":"1181_CR145","doi-asserted-by":"publisher","first-page":"adv34206","DOI":"10.2340\/actadv.v104.34206","volume":"104","author":"CH Bang","year":"2024","unstructured":"Bang, C. H. et al. Ustekinumab demonstrates lower uveitis risk in moderate to severe psoriasis patients compared with tumor necrosis factor-\u03b1 inhibitors. Acta Derm. Venereol. 104, adv34206 (2024).","journal-title":"Acta Derm. Venereol."},{"key":"1181_CR146","unstructured":"Roche. Vamikibart in participants with uveitic macular edema. ForPatients by Roche https:\/\/forpatients.roche.com\/en\/trials\/eye-disorder\/uveitic-macular-edema\/ro7200220-in-participants-with-uveitic-macular-edema-91001.html#formedicalprofessionals (2024)."},{"key":"1181_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43036-1","volume":"14","author":"S Gelfman","year":"2023","unstructured":"Gelfman, S. et al. A large meta-analysis identifies genes associated with anterior uveitis. Nat. Commun. 14, 7300 (2023).","journal-title":"Nat. Commun."},{"key":"1181_CR148","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ajhg.2022.12.017","volume":"110","author":"S Burgess","year":"2023","unstructured":"Burgess, S. et al. Using genetic association data to guide drug discovery and development: review of methods and applications. Am. J. Hum. Genet. 110, 195\u2013214 (2023).","journal-title":"Am. J. Hum. Genet."},{"key":"1181_CR149","doi-asserted-by":"publisher","unstructured":"Wu, K. Y., Tan, K., Akbar, D., Choulakian, M. Y. & Tran, S. D. A new era in ocular therapeutics: advanced drug delivery systems for uveitis and neuro-ophthalmologic conditions. Pharmaceutics 15, https:\/\/doi.org\/10.3390\/pharmaceutics15071952 (2023).","DOI":"10.3390\/pharmaceutics15071952"},{"key":"1181_CR150","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jconrel.2021.03.035","volume":"333","author":"L Rebibo","year":"2021","unstructured":"Rebibo, L. et al. Topical tacrolimus nanocapsules eye drops for therapeutic effect enhancement in both anterior and posterior ocular inflammation models. J. Control. Rel. 333, 283\u2013297 (2021).","journal-title":"J. Control. Rel."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01181-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01181-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01181-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T14:04:22Z","timestamp":1732197862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01181-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":150,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1181"],"URL":"https:\/\/doi.org\/10.1038\/s41584-024-01181-x","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"7 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.L.N.C. declares that they are a full-time employee of AstraZeneca.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}